Literature DB >> 22930509

Hepatitis C virus infection among drug addicts in Italy.

T Stroffolini1, P F D'Egidio, A Aceti, P Filippini, M Puoti, C Leonardi, P L Almasio.   

Abstract

There is a lack of updated nationwide records regarding hepatitis C virus (HCV) infection among drug addicts in Italy. The prevalence and characteristics of HCV infection in a national sample of drug addicts in Italy were determined. Five hundred forty-three drug addicts (mean age 35.3 years, 85.1% males), selected from 25 Italian Centers for Substance Dependence were enrolled to be evaluated for anti-HCV, HCV-RNA, HCV genotype, HBV markers, anti-HDV, and anti-HIV during the period of April-November 2009. Anti-HCV prevalence was 63.9%. HCV-RNA was detected in 68.3% of patients positive for anti-HCV. Genotypes 1 and 3 prevailed (49.3% and 39.7%, respectively). However, 9.3% of the subjects had genotype 4, a rate over threefold higher than the one observed in 1996 among drug addicts in central Italy. Needle sharing was the strongest independent predictor of the likelihood to contract an HCV infection (OR 8.9; 95% CI: 5.0-16.0). Only 19.3% of subjects received antiviral treatment for HCV. The prevalence of HBsAg and HIV positivity was 2.8% and 3.1%, respectively. The pattern of HBV markers showed that nearly one-third of subjects had been vaccinated, while 42.3% were negative for any marker of HCV. The prevalence of HCV infection is high among drug addicts in Italy. The incidence of Genotype 4 is increasing and this may lead to the spreading of the disease to the general population in the near future. Efforts should be made to improve the rate of antiviral treatment for drug addicts with HCV infection and vaccination against hepatitis B.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22930509     DOI: 10.1002/jmv.23370

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  13 in total

1.  Incidence and Risk Factors for Hepatitis C Virus Infection among Illicit Drug Users in Italy.

Authors:  Enea Spada; Giovanni Rezza; Anna Rosa Garbuglia; Flavia Lucia Lombardo; Ornella Zuccaro; Francesca Menniti Ippolito; Elisabetta Cupellaro; Stefania Capone; Maria Rosaria Capobianchi; Alfredo Nicosia; Riccardo Cortese; Antonella Folgori; Alfonso Mele
Journal:  J Urban Health       Date:  2018-02       Impact factor: 3.671

Review 2.  Current and future challenges in HCV: insights from an Italian experts panel.

Authors:  Massimo Andreoni; Sergio Babudieri; Savino Bruno; Massimo Colombo; Anna L Zignego; Vito Di Marco; Giovanni Di Perri; Carlo F Perno; Massimo Puoti; Gloria Taliani; Erica Villa; Antonio Craxì
Journal:  Infection       Date:  2017-11-02       Impact factor: 3.553

3.  Telemedicine Improves HCV Elimination among Italian People Who Use Drugs: An Innovative Therapeutic Model to Increase the Adherence to Treatment into Addiction Care Centers Evaluated before and during the COVID-19 Pandemic.

Authors:  Valerio Rosato; Riccardo Nevola; Vincenza Conturso; Pasquale Perillo; Davide Mastrocinque; Annalisa Pappalardo; Teresa Le Pera; Ferdinando Del Vecchio; Ernesto Claar
Journal:  Biology (Basel)       Date:  2022-05-24

Review 4.  Epidemiology of hepatitis C in Croatia in the European context.

Authors:  Tatjana Vilibic-Cavlek; Jasmina Kucinar; Bernard Kaic; Maja Vilibic; Nenad Pandak; Ljubo Barbic; Vladimir Stevanovic; Jasmina Vranes
Journal:  World J Gastroenterol       Date:  2015-08-28       Impact factor: 5.742

5.  HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes.

Authors:  Anna Rosa Garbuglia; Alessia Monachetti; Claudio Galli; Rosella Sabatini; Monica Lucia Ferreri; Maria Rosaria Capobianchi; Patrizia Bagnarelli
Journal:  BMC Infect Dis       Date:  2014-04-23       Impact factor: 3.090

Review 6.  Hepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and prevention.

Authors:  Lucas Wiessing; Marica Ferri; Bart Grady; Maria Kantzanou; Ida Sperle; Katelyn J Cullen; Angelos Hatzakis; Maria Prins; Peter Vickerman; Jeffrey V Lazarus; Vivian D Hope; Catharina Matheï
Journal:  PLoS One       Date:  2014-07-28       Impact factor: 3.240

7.  Correlates of infection and molecular characterization of blood-borne HIV, HCV, and HBV infections in HIV-1 infected inmates in Italy: An observational cross-sectional study.

Authors:  Nunzia Sanarico; Stefania D'Amato; Roberto Bruni; Claudia Rovetto; Emanuela Salvi; Patrizia Di Zeo; Paola Chionne; Elisabetta Madonna; Giulio Pisani; Angela Costantino; Michele Equestre; Maria E Tosti; Alessandra Cenci; Maria T Maggiorella; Leonardo Sernicola; Emanuele Pontali; Alfredo Pansera; Rocco Quattrocchi; Sergio Carbonara; Fabio Signorile; Lorenzo Antonio Surace; Guido Federzoni; Elisa Garlassi; Giulio Starnini; Roberto Monarca; Sergio Babudieri; Maria Rapicetta; Maria G Pompa; Anna Caraglia; Barbara Ensoli; Anna R Ciccaglione; Stefano Buttò
Journal:  Medicine (Baltimore)       Date:  2016-11       Impact factor: 1.889

8.  HCV elimination among people who inject drugs. Modelling pre- and post-WHO elimination era.

Authors:  Ilias Gountas; Vana Sypsa; Sarah Blach; Homie Razavi; Angelos Hatzakis
Journal:  PLoS One       Date:  2018-08-16       Impact factor: 3.240

9.  Distribution of HCV genotypes in the populations of inmates in polish prison potulice and patients hospitalised in bydgoszcz.

Authors:  Malgorzata Tyczyno; Waldemar Halota; Wojciech Nowak; Małgorzata Pawlowska
Journal:  Hepat Mon       Date:  2014-05-03       Impact factor: 0.660

Review 10.  Epidemiological burden estimates for pathologies with a nonconstant risk: an application to HCV in Italy according to age, Metavir score, and genotype: A systematic review and meta-analysis.

Authors:  Rossella Letizia Mancusi; Massimo Andreoni; Daniela d'Angela; Cesare Sarrecchia; Federico Spandonaro
Journal:  Medicine (Baltimore)       Date:  2016-10       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.